Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000886163-18-000056
Filing Date
2018-04-30
Accepted
2018-04-30 16:08:25
Documents
11
Period of Report
2018-04-27
Effectiveness Date
2018-04-30

Document Format Files

Seq Description Document Type Size
1 DEF 14A lgnd-2018annualmeetingproxy.htm DEF 14A 916603
2 a02szebligandpharmaceuti001.jpg GRAPHIC 225041
3 a02szebligandpharmaceuti002.jpg GRAPHIC 103067
4 a02szicligandpharmaceuti001.jpg GRAPHIC 206421
5 a02szicligandpharmaceuti002.jpg GRAPHIC 160119
6 image0.jpg GRAPHIC 9775
7 image1a01.gif GRAPHIC 565
8 image2.gif GRAPHIC 1174
9 image3.gif GRAPHIC 612
10 image4.gif GRAPHIC 431
11 stockreturngraph2017.jpg GRAPHIC 86451
  Complete submission text file 0000886163-18-000056.txt   1998717
Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

EIN.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33093 | Film No.: 18789737
SIC: 2834 Pharmaceutical Preparations